Health ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Monoclonal Antibodies Obesity Treatments FDA Approval Semaglutide Efficacy Studies Lenacapavir Osteogenesis Imperfecta Retatrutide Regulatory Approval Phase 3 Trials

Neumora Halts Navacaprant After Phase 3 KOASTAL Failures

A roughly 35% workforce reduction will fund a pivot to three earlier-stage programs, preserving cash into the third quarter of 2027.

FDA Places Full Clinical Hold on Aardvark’s ARD-101 Prader–Willi Trials

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

FDA Chief Makary Faces Intensifying Pressure as Vape Approvals and Staff Shake-Up Fuel Scrutiny

Medicus Pharma Reports Long-Acting Hormone Control in Phase 1 Teverelix Data

UniQure Investors Face Lead‑Plaintiff Deadline in Securities Fraud Case

Ultragenyx Hit With Securities Class Action Over Failed Phase III Trials

Cancer Study Maps Brain Metastasis Switch and Identifies Ibudilast as a Repurposing Candidate

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

AIM ImmunoTech Secures Final Japan Patent for Ampligen Checkpoint-Inhibitor Cancer Therapy

EMA Backs Single-Dose Acoziborole for Gambiense Sleeping Sickness Outside EU

Japan Panel Clears iPS Cell Therapies for Heart Failure and Parkinson’s

Insmed Sets $1 Billion 2026 Brinsupri Target After Strong First Full Quarter

NCI Pursues Preclinical Test of Ivermectin’s Anti-Cancer Activity

Lilly and Innovent Forge Territory-Split Cancer and Immunology Alliance

Vistagen Hit With Securities Class Actions After Phase 3 Miss as Investors Face March 16 Deadline

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Nimacimab Disclosures

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years